Form 4: Verve Therapeutics Executive Granted Stock Options and Restricted Stock Units

Jason Politi, Chief Technical Operations Officer at Verve Therapeutics, received stock options and restricted stock units as part of his compensation.

Summary

• Jason Politi, Chief Technical Operations Officer of Verve Therapeutics, was granted stock options for 225,000 shares at an exercise price of $6.01 on January 8, 2025.
• These options vest over a period of four years, with 25% vesting on January 8, 2026, and the remainder vesting monthly until January 8, 2029.
• Politi also received 40,000 restricted stock units (RSUs) on the same date.
• These RSUs vest in three equal annual installments starting on April 1, 2026, and continuing on April 1, 2027 and April 1, 2028.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, which is generally positive for aligning executive and shareholder interests. There are no negative implications.

Positives

• The grant of stock options and restricted stock units aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Risks

• The value of the stock options and RSUs is dependent on the future performance of Verve Therapeutics' stock price.
• There is a risk that the executive may leave the company before all options and RSUs have vested.

Future Outlook

The document does not contain any forward-looking statements or guidance.

Industry Context

The granting of stock options and restricted stock units is a common practice in the biotechnology industry to attract and retain key talent.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice for executive compensation in the biotech industry.
• Vesting schedules are also typical, designed to incentivize long-term performance and retention.
• The specific amounts and vesting terms would need to be compared to similar companies to assess if they are above or below industry averages.

Stakeholder Impact

• Shareholders may view the grants as a positive sign of the company's commitment to retaining key personnel.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, executive compensation, vesting, Verve Therapeutics, VERV, Jason Politi